Assessing PFS in NSCLC: TROPION-Lung01 Commentary by Bornstein-Quevedo & Dueñas-Gonzalez

Описание: This commentary examines the TROPION-Lung01 Phase III study, which compares datopotamab deruxtecan with docetaxel in patients with pretreated advanced non-small cell lung cancer. The study found that datopotamab deruxtecan significantly improves progression-free survival, particularly in nonsquamous histology, and has a favorable safety profile compared to docetaxel. However, no significant improvement in overall survival was observed, and there are concerns regarding increased progression risk in squamous histology patients. The authors discuss the study’s adherence to CONSORT guidelines and the implications for communicating treatment options to patients.

📜 Paper title: "TROPION-Lung01 Results Indicate PFS Benefit with Datopotamab Deruxtecan over Docetaxel in Previously Treated Nonsquamous NSCLC: A Critique and Question"

👨‍🏫 Authors: Leticia Bornstein-Quevedo, Alfonso Dueñas-Gonzalez

🔗 Full text on Qeios: https://doi.org/10.32388/1PO7Y7

#NSCLC #LungCancer #CancerResearch #Oncology #DatopotamabDeruxtecan #TROPIONLung01 #MedicalResearch